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Background: RABEX-5, a guanine nucleotide exchange factor (GEF) for RAB-5, plays an important role in cell
mobility and altered expression associated with tumor metastasis. This study aimed to investigate the role of
RABEX-5 in proliferation and metastasis of breast cancer in vitro and ex vivo.
Methods: RABEX-5 expression was examined in breast cancer, benign tumor and normal breast tissues by
immunohistochemistry and western blot. Two stable cell lines were established, the MCF-7/NC negative control cell
line and the MCF-7/KD cell line, which stably expressed an RNA interference (RNAi) construct that induced
downregulation of RABEX-5 expression. These cell lines were utilized to evaluate the role of RABEX-5 in cell
proliferation and migration in vitro and tumorigenicity in vivo. The possible role of RABEX-5 in the regulation of
matrix metallopeptidase 9 (MMP-9) was evaluated using western blot and real-time PCR.
Results: RABEX-5 expression was found to be significantly higher in breast cancer tissues compared with benign
tumor and normal breast tissues. High levels of RABEX-5 expression were associated with axillary lymph node
metastasis. In addition, RABEX-5 silencing significantly reduced cancer cell proliferation, colony formation and
migration ability in vitro and inhibited tumor growth in vivo. RABEX −5 knockdown also attenuated the migration
of breast cancer cells via modulation of MMP-9 transcriptional activity.
Conclusions: Our results indicate that RABEX-5 plays an oncogenic role in breast cancer by modulating the
proliferation and metastasis potential of breast cancer cells. Thus, RABEX-5 is a promising prognostic indicator for
patients with breast cancer.
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Breast cancer is a systemic disease. It has become the
most frequently diagnosed cancer and the leading cause
of cancer death in females worldwide, with rapidly in-
creasing incidence and mortality rates. Breast cancer
accounted for 23% (1.38 million) of total new cancer cases
and 14% (458,400) of total cancer deaths in 2008 [1]. The
incidence rates of breast cancer vary from 19.3 per 100,000
women in Eastern Africa to 89.7 per 100,000 women in
Western Europe, while the mortality rate is approximately
6–19 per 100,000 [2].* Correspondence: hongy_li@hotmail.com
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reproduction in any medium, provided the orTumorigenesis is a multifactor, multistep complex
process that involves the cooperation of many genes, in
particular the activation of oncogenes and inactivation of
tumor suppressor genes. Recent clinical data have emerged
demonstrating that Ras family genes play important roles
in human tumorigenesis. The activation of Ras proteins by
mutational activation or by growth factor stimulation is
a common occurrence in many human cancers and was
shown to induce and to be required for tumor growth.
The Ras superfamily of small guanosine triphosphatases
(GTPases) contains over 150 human members, with the
Ras oncogene proteins as the founding members of this
family, which is divided into five major branches on the
basis of sequence and functional similarities: Ras, Rho,
Rab, Ran and Arf.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ism. The Ras superfamily of GTPases function as GDP/
GTP-regulated molecular switches. They alternate be-
tween GTP- and GDP-bound conformations in which
the GTP-bound conformation represents the “on” state
and the GDP-bound conformation represents the “off”
state. Upon binding, two regions of Ras undergo dra-
matic structural changes depending on the type of
bound nucleotide [3]. Small GTPases exhibit high-affinity
binding for GDP and GTP and possess low intrinsic GTP
hydrolysis and GDP/GTP exchange activities. GDP/GTP
cycling is controlled by two main classes of regulatory
proteins. Guanine-nucleotide-exchange factors (GEFs)
promote the formation of the active, GTP-bound form,
whereas GTPase-activating proteins (GAPs) accelerate
the intrinsic GTPase activity to promote formation of the
inactive, GDP-bound form [4,5]. GTPases within a branch
use shared and distinct GAPs and GEFs. GTPases in differ-
ent branches exhibit structurally distinct but mechanistic-
ally similar GAPs and GEFs. The two nucleotide-bound
states have similar conformations but have pronounced
differences corresponding to the switch I (Ras residues
30–38) and switch II (59–67) regions; the GTP-bound
conformation possesses high affinity for effector targets
[6,7]. It is mainly through the conformational changes
in these two switches that the regulatory proteins and
effectors modulate the nucleotide status of the small
GTPases [8].
Ras-associated binding (Rab)-GTPases are members of
the Ras family of small GTPases. The Rab family pro-
teins regulate a variety of membrane trafficking events
in all eukaryotic cells by recruiting specific effector mol-
ecules. They are important for the regulation of signal
transduction and cellular processes such as differenti-
ation, proliferation, vesicle transport, nuclear assembly
and cytoskeleton formation, and they are abnormally
expressed in various cancer tissues [9]. Rab GTPases
regulate membrane trafficking between organelles by re-
cruitment of effector proteins. Immunodeficiencies, can-
cer, and neurological disorders are associated with
functional impairments of the Rab signaling pathways
[10]. Alterations or mutations in the Rab proteins and
their effectors have been suggested to cause many human
diseases, including cancer. In particular, previous reports
have demonstrated that alterations in RAB-25, RAB-7,
RAB-5, and RAB-11 could cause different types of can-
cer. Rab family proteins are also involved in exocytosis in
endocrine cells and are associated with the invasive and
metastatic potential of breast cancer by promoting the
production of insulin-like growth factor-II (IGF-II). The
rate of secretion controls the expression of vascular endo-
thelial growth factor (VEGF), matrix metalloproteinase-9
(MMP-9), cathepsin D, cyclin D1, p16, and urokinase-type
plasminogen activator [11].The small GTPase RAB-5, which is found at the plasma
membrane and early endosomes, is a master regulator of
early endocytic trafficking [12]. Like other small GTPases,
RAB-5 is activated by an exchange of bound GDP with
GTP, which is catalyzed by a family of guanine-nucleotide-
exchange factors (GEFs). RABEX-5 was identified as an
interactor of Rabaptin-5 and was found to possess GEF ac-
tivity toward RAB-5 and related GTPases. Likewise, both
Rabaptin-5 and RABEX-5 are essential for RAB-5-driven
endosome fusion in vitro [13].
Aberrant RABEX-5 expression may result in obstruc-
tion of the RAB-5-mediated endocytic vesicle fusion
process, thereby causing defects in phagocytosis. A pre-
vious study found that RABEX-5 was over-expressed in
colorectal tumor cell lines [14]. The authors also hinted
that RABEX-5 may act as an oncogene that is involved
in the formation and development of malignant tumors
and might influence tumor biological behavior. However,
the role and mechanism of action of RABEX-5 in breast
cancer carcinogenesis and progression have not yet been
determined. In this study, we first analyzed the expres-
sion of RABEX-5 in breast cancer tissue and breast can-
cer cell lines by immunohistochemistry and real-time
PCR. Subsequently, the influence of the biological func-
tion of breast cancer was evaluated in vitro and vivo.
Our results showed that RABEX-5 was overexpressed
and plays a distinct oncogenic role in breast cancer.
Materials and methods
Patients and tissue samples
A total of 60 invasive ductal carcinoma breast tissue
samples, 15 normal breast tissue samples, and 15 benign
breast tumor tissue samples were obtained from patients
who underwent surgical treatment at the First Affiliated
Hospital of Chongqing Medical University from February
to May in 2009 after obtaining informed consent. None
of the patients received therapy before surgery. The
tissues from all of the patients were staged according to
the American Joint Committee on Cancer (AJCC) breast
cancer TNM staging system: stage I, n = 29; stage II,
n = 25; and stage III, n = 6. All tissue samples were fixed
in 10% formalin and then embedded in paraffin for histo-
logic examination.
Immunohistochemistry
Immunohistochemical staining was performed on paraffin-
embedded specimens. Slides were routinely deparaffinized
and hydrated. Endogenous peroxidase was blocked with
3% hydrogen peroxide for 10 min, and the deparaffinized
sections in 10 mM citrate buffer were microwaved for
30 minutes for epitope retrieval. Then, the sections were
incubated with an antibody against RABEX-5 (1:50 dilu-
tion, Santa Cruz Biotechnology, USA) and an antibody
against MMP-9 (1:100 dilution, Ab76003, Abcam, UK) for
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buffered saline (PBS). A secondary antibody was added and
incubated for 1 h at 37°C. The sections were counter-
stained with hematoxylin for 3–5 min. PBS, instead
of primary antibody, was used as a negative control.
For the evaluation of expression, IPP (version 6.0,
Media Cybernetics, Silver Spring, MD) was used as
described previously [15]. Briefly, 5 digital images at
1360×1024 pixel resolution and 400 × magnification
were captured by the LEICA DM500 ICC50 microscope
(Leica Microsystems, Germany). The measurement pa-
rameters included area, sum, and IOD, and the values
were counted.
Cell lines and culture conditions
Five breast cancer cell lines (MCF-7, MDA-MB-231,
BT549, T47D and SKBR3) were used. All cell lines were
obtained from the Molecular Oncology and Epigenetics
Laboratory of The First Affiliated Hospital of Chongqing
Medical University. Cell lines were routinely maintained
in RPMI 1640 medium supplemented with 10% fetal
bovine serum (GIBCO, Grand Island, NY) in a 5% CO2
atmosphere at 37°C.
RNA extraction, reverse transcription, and real-time
PCR analysis
Total RNA was isolated from tissues and cells using
Trizol (Invitrogen, USA) according to the manufacturer’s
instructions. Reverse transcription was performed using
random hexamers, and reverse transcription-PCR using
Go-Taq (Promega, Madison, WI, USA), with GAPDH as
a control, was performed using the following primers:
RABEX-5 F: 5′-TTGGACAGATGGAATTGCAA-3′ and
RABEX-5R: 5′-GTTGCAGTGGTGGAGGAAGT-3′. The
PCR program consisted of initial denaturation at 95°C for
2 min, followed by 32 cycles (for RABEX-5) or 23 cycles
(for GAPDH) of the reaction (94°C for 30 s, 55°C for 30 s
and 72°C for 30 s), with a final extension at 72°C for
10 min. Quantitative real-time PCR was performed using
the SYBR Premix Ex Taq™ kit (TAKARA, Japan). After
an initial denaturation step at 95°C for 30 s, thermal
cycling was initiated. Each cycle consisted of 95°C for
5 s and 60°C for 34 s. The fluorescent signal was acquired
at the end of the elongation step. A total of 40 cycles was
performed. The nucleotide sequences of the primers used
for PCR amplification were as follows: (1)RABEX-5 F: 5′-
TTGGACAGATGGAATTGCAA-3′ and RABEX-5R: 5′-
GTTGCAGTGGTGGAGGAAGT-3′(GenBank accession
No. NM_004994), (2)MMP-9 F: 5′-CCTGGAGACCTG
AGAACCAATC-3′ and MMP-9R: 5′-CCACCCGAGTG
TAACCATAGC-3′(GenBank accession No. NM_014504),
(3)GAPDH-F: 5′-TCCTGTGGCATCCACGAAACT-3′
and GAPDH-R: 5′-GAAGCATTTGCGGTGGACGAT-3′
(GenBank accession No. NM_001101). The comparativeCt (threshold cycle) method was used to calculate the
relative changes in gene expression obtained from the
real-time PCR system.
RNA interference
An siRNA vector was generated by ligating DNA oligos
into the linear pMAGic-siR lentiviral plasmid vector.
This vector was used to inhibit human RABEX-5 gene
expression (GenBank accession No. NM_014504). As a
control, the pMAGic-siR-neg lentiviral control plasmid
encoding an mRNA not known to target any verte-
brate gene was used. The RABEX-5 siRNA targeting
oligo was 5′-GGATGCAAACTCGTGGGAA-3′, while the
non-homologous sequence used as the control was 5′-
TTCTCCGAACGTGTCACGT-3′.
After the lentiviral vector to perform RNA interference
(RNAi) of the RABEX-5 gene was constructed, the re-
combinant lentiviral plasmid and the control lentiviral
plasmid were transfected into MCF-7 cells. The cells
with the most appropriate level of transfection were
selected. Real-time PCR and western blot analyses were
used to examine the expression of RABEX-5.
Colony formation assay and cell proliferation assay
MCF-7 cells transfected with the pMAGic-siR lentiviral
plasmid vector (MCF-7/KD) and the pMAGic-siR-neg
lentiviral control plasmid (MCF-7/NC) were plated in
6-well plates (2×103 cells/well). The number of colonies
(>50 cells per colony) was counted after staining with
Giemsa 14 days later, and the colonies were photographed.
Each experiment was performed in triplicate three times.
A Cell Count Kit-8 (CCK-8, Beyotime, China) was
employed to quantitatively evaluate cell viability. Briefly,
2×103 cells/well were seeded in 96-well flat-bottomed
plates, then grown at 37°C for, 24, 48, 72, and 96 h.
Then, the original medium in each well was replaced by
200 μl 10% FBS/RPMI 1640 medium contain 20 μl CCK-8.
The cells were incubated at 37°C for 2 h, and the absorb-
ance was determined at wavelengths of 450 nm and
630 nm (calibrated wave) using a microplate reader. RPMI
1640 containing 10% CCK-8 was used as a control.
Wound healing assay and transwell cell migration assay
The mobility of MCF-7/KD and MCF-7/NC cells was
assessed using a scratch wound assay. We drew horizon-
tal lines across the back of the wells of 6-well plates with
a marker pen. The cells (5×105 cells/well) were plated
into the 6-well plates. On the following day, the conflu-
ent cell monolayers were carefully wounded (perpen-
dicular to the horizontal lines) with sterile pipette tips
and washed with PBS twice to remove cellular debris.
Serum-free medium was added into the wells. Then, the
wounded cell monolayers were cultured for another 48 h.
Images were captured under a fluorescent microscope to
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different timepoints.
A cell migration assay was performed using transwell
chambers with a pore size of 0.8 μm. A total of 1×105
cells were seeded in serum-free medium in the upper
chamber, while medium containing 10% FBS was added
as a chemoattractant to the lower chamber. After incu-
bating for 48 h at 37°C, the cells in the upper chamber
were carefully removed with a cotton swab, and the
cells that had migrated to the reverse face of the mem-
brane were fixed in methanol, stained with Giemsa, and
counted.
Mouse tumor transplantation models
In vivo studies were conducted in immunodeficient mice.
Six female athymic mice, weighing 18–20 g at 4 weeks of
age, were obtained from the Beijing Laboratory Animal Re-
search Center (Beijing, China). All mice were handled
according to the recommendations of the National Insti-
tutes of Health Guidelines for Care and Use of Laboratory
Animals. The MCF-7/KD cells were inoculated subcutane-
ously into the right flanks of the mice (2×106 cells/mouse),
while the MCF-7/NC cells were inoculated subcutaneously
into the left flanks of the mice (2×106 cells/ mouse).
Tumor size was measured externally every 3 days using a
caliper, and tumor volume was estimated using the equa-
tion: length (mm) × width2 (mm) × 0.52. The mice were
sacrificed 4 weeks after the transplant, and the tumors
were weighed after dissection. Samples from each area
were snap-frozen at −80°C for protein preparation, and the
corresponding tissue samples were fixed in 4% formalin to
obtain paraffin-embedded sections.
Western blot
After protein lysates were prepared, an equivalent amount
of protein from each sample was loaded onto an SDS
polyacrylamide gel. The protein lysates were then sepa-
rated by SDS-PAGE and electroblotted onto PVDF mem-
branes. After blocking with 5% nonfat milk and 0.1%
Tween 20 in TBS, the membranes were incubated with
rabbit anti-RABEX-5 (1:200 dilution; Santa Cruz Bio-
technology, USA), rabbit anti-MMP-9 (1:1000 dilution;
Ab76003, Abcam, UK) and rabbit anti-GAPDH (1:2000
dilution; Ab9485, Abcam, UK) antibodies overnight at 4°C.
Then, the membranes were incubated with a horseradish
peroxidase-conjugated secondary antibody at a dilution of
1:1000 for 1 h. The blots were visualized using ECL Plus
Western Blotting Detection Reagents (Beyotime, China)
and scanned.
Statistical analyses
Statistical analyses were performed using SPSS 16.0 soft-
ware. Expression analysis, original real-time PCR data,
western blot data, migration data, and colony formationdata were recorded as continuous variables and analyzed
using Student’s t-test. Differences were considered statis-
tically significant if the P value was less than 0.05.
Results
Expression of RABEX-5 in tissues and breast cancer
cell lines
We first examined the expression of RABEX-5 using
IHC in breast cancer, benign breast tumor and nor-
mal breast tissues. The immunostaining quantification
of RABEX-5 was analyzed using Image Pro-Plus (IPP).
Our results showed that the RABEX-5 expression in
breast cancer tissues was significantly higher than that
in the benign breast tumor tissues and normal breast
tissues (Figure 1A). Western blot analyses confirmed
that RABEX-5 expression at the protein level was con-
sistent with the IHC results (Figure 1C). Next, the ex-
pression level of RABEX-5 was analyzed in 5 breast
cancer cell lines (MCF-7, MDA-MB-231, BT549, T47D,
and SKBR3). RABEX-5 was overexpressed in all of the
breast cancer cell lines (Figure 1B). These results sug-
gest that RABEX-5 is frequently upregulated in breast
cancer.
We further investigated the role of RABEX-5 in breast
cancer by examining the relationship between RABEX-5
expression and the clinicopathologic features of breast
cancer. RABEX-5 expression was associated with tumor
size and axillary lymph node metastases (P<0.05) (Table 1,
Figure 1D) but not with age, grade, and ER, PR, and
C-erBb-2 status (P>0.05), suggesting that there is a rela-
tionship between RABEX-5 overexpression and breast can-
cer metastasis.
RABEX-5 gene downregulation in MCF-7 cells
To investigate whether decreased RABEX-5 expression
can influence the biological behavior of breast cancer
cell lines, an siRNA vector targeting the RABEX-5 gene
was constructed. The effectiveness of the 4 siRNA oligos
targeting RABEX-5 was verified (Table 2), and a re-
duction in the endogenous RABEX-5 expression was
detected by real-time PCR in MCF-7 cells (P <0.05; data
not shown). We selected the most promising candidate to
be recombined into the RABEX-5-siRNA lentiviral vector,
which was then transfected into MCF-7 cells (MCF-7/KD).
MCF-7/KD cells showed a significant decrease in RABEX-
5 mRNA and protein expression levels compared with
MCF-7 cells (CON) or negative control-transduced cells
(MCF-7/NC) (Figure 2A, Figure 2B).
Downregulation of RABEX-5 inhibits colony formation
and breast cancer cell proliferation
A CCK-8 assay was used to further explore the ability of
RABEX-5 to modulate breast cancer cell proliferation.
The MCF-7/KD group displayed significantly decreased
Figure 1 Expression of RABEX-5 in breast cancer. (A), Expression of RABEX-5 in Breast cancer, Benign tumor, and Normal breast tissue.
The distinct brown staining was located in the cytoplasm of positive cells. (B), Benign tumor tissue, Normal breast tissue and breast cancer
cell lines were evaluated using semi-quantitative RT-PCR, with GAPDH as a control. (C), RABEX-5 protein expression was detected in breast
cancer tissue, Benign tumor tissue and Normal breast tissue by western blot. (D), Expression of RABEX-5 and its relationship with axillary
lymph node metastases.
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compared with the MCF-7/NC group (P<0.05, Figure 2C).
Meanwhile, the colony formation assay further revealed
the effects of RABEX-5 knockdown on the growth of
MCF-7 cells. Downregulation of RABEX-5 markedlysuppressed the colony formation ability of MCF-7 cells.
The MCF-7/KD group had reduced positive colony for-
mation than the MCF-7/NC group (P<0.05, Figure 2D).
These data suggest that downregulation of RABEX-5
suppresses breast cancer cell proliferation.
Table 1 Relationship of RABEX-5 mRNA and protein






Axillary lymph nodes P<0.001
Metastasis 27 0.329±0.144* 0.308±0.131*
No metastasis 33 0.180±0.070* 0.168±0.066*
Tumor size(cm) P<0.05
≤2 cm 29 0.223±0.087 0.209±0.085
>2 cm,≤5 cm 24 0.238±0.150# 0.222±0.140#
>5 cm 7 0.358±0.139# 0.328±0.119#
Histologic grade P>0.05
I 29 0.229±0.138 0.205±0.128
II 25 0.279±0.123 0.251±0.113
III 6 0.299±0.127 0.279±0.123
ER P>0.05
Positive 27 0.276±0.159 0.256±0.145
Negative 33 0.227±0.101 0.215±0.171
PR P>0.05
Positive 26 0.275±0.163 0.256±0.148
Negative 34 0.228±0.099 0.216±0.097
HER-2 P>0.05
Positive 16 0.232±0.128 0.217±0.119
Negative 44 0.255±0.134 0.239±0.124
# P<0.05, vs. tumor size >2 cm, ≤5 cm group and >5 cm group.
* P<0.001, vs. node metastasis group and no metastasis group.
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of breast cancer cells
To investigate the role of RABEX-5 in breast cancer metas-
tasis, we investigated the migratory and invasive capacity
of MCF-7/KD and MCF-7/NC cells. To test whether
downregulation of RABEX-5 could inhibit tumor cell mi-
gration, a wound healing assay was performed. The migra-
tion of MCF-7/KD cells across the wound edges was
remarkably slower than that of the MCF-7/NC cells at
54 h (Figure 3A). From the transwell assay, we found that
the percentage of MCF-7/KD cells that migrated through






pLVT7 NC TTCTCCGAACGTGTCACGTMCF-7/NC cells (P<0.05, Figure 3B). These results indicate
that the downregulation of RABEX-5 inhibits the migration
of breast cancer cells and that RABEX-5 indeed possesses
the ability to promote tumor metastasis and can function
as an oncogene in breast cancer.
Knockdown of RABEX-5 suppresses the expression
of MMP-9
MMP-9 is a matrix metalloproteinase that was previously
shown to play a critical role in the tumor microenviron-
ment by enhancing cancer cell motility, angiogenesis and
cancer growth [16]. Our data have demonstrated that
RABEX-5 can promote the migration and invasion of
breast cancer cells; however, it is unknown whether
RABEX-5 can modulate MMP-9 expression. Therefore,
we next examined the expression level of MMP-9 in
MCF-7/KD and MCF-7/NC cells using real-time PCR.
The expression of MMP-9 was significantly reduced
in MCF-7/KD cells compared with MCF-7/NC cells
(P<0.05, Figure 3C). These data suggest that knockdown
of RABEX-5 suppresses the metastasis of breast cancer
cells through the modulation of MMP-9 transcriptional
activity.
Gene silencing of RABEX-5 inhibits breast cancer growth
in vivo
Based on the in vitro findings described above, we exam-
ined the effect of RABEX-5 silencing on tumor growth
in vivo. Xenografts in nude mice were established by
subcutaneous injection of MCF-7/KD cells and MCF-
7/NC cells into nude mice as described in the Materials
and Methods section. Tumor size was monitored every
3 days with a caliper. The tumor growth of the xenografts
derived from the MCF-7/NC group was comparable to
that of the MCF-7/KD group, showing a marked increase
in tumor volume 4 weeks after tumor cell inoculation
(P<0.05, Figure 4A, Figure 4B, Figure 4C). In addition, the
final mean tumor weight of the MCF-7/KD group was
significantly lighter than that of the MCF-7/NC group
(P<0.05, Figure 4D), indicating that the silencing of
RABEX-5 causes an inhibition of growth of MCF-7 tumors
in vivo. Next, western blotting was used to examine the ex-
pression of RABEX-5 and MMP-9 in transplantation
tumor samples. As shown in Figure 4E, the protein expres-
sion level of RABEX-5 and MMP-9 in the MCF-7/KD
group was decreased compared with the MCF-7/KD group
(P<0.05). Immunohistochemistry was also used to deter-
mine the protein expression of RABEX-5 and MMP-9 in
the tumor sections. Analysis of RABEX-5 and MMP-9
expression in tumors derived from the MCF-7/NC group
indicated strong staining throughout the tumor mass,
whereas tumors from the MCF-7/KD group showed
less staining only in part of the areas of the tumor mass
Figure 2 Downregulation of RABEX-5 in MCF-7 cell and effects of RABEX-5 on the colony formation and cell proliferation of breast
cancer cells. (A), RABEX-5 mRNA levels were analyzed by real time-PCR. MCF-7 cells were transfected with pMAGic-siR lentiviral plasmid (MCF-7/
KD) and pMAGic-siR-neg lentiviral control plasmid (MCF-7/NC). (B), RABEX-5 protein levels in MCF-7/KD and MCF-7/NC were analyzed by western
blot. GAPDH was used as an internal control. P<0.05 compared with normal control (MCF-7) or MCF-7/NC. (C), CCK-8 cell proliferation assay
for vector- and RABEX-5-transfecetd MCF-7 cells, curves indicate a significant level of proliferation compared to controls(P <0.05). (D),
Representative colony formation assay, the numbers of colonies in MCF-7/NC were set to 100%. Values are expressed as mean±SD from three
experiments, and the asterisks indicate statistical significance compared to controls (P<0.05).
Figure 3 Downregulation of RABEX-5 expression inhibits cell migration. (A), Wound healing assay with MCF-7/NC and MCF-7/KD cells.
Microscopic observations were recorded 0 and 54 hours after scratching the cell surface. a representative image from three independent
experiments is shown. (B), Transwell assay. Photographs represented the cells travelled through the micropore membrane and histogram showed
the percentage of migrant cells. (C), MMP-9 mRNA expression was evaluated by real time-PCR. The asterisk indicates statistical significant difference
(P<0.05). Original magnification, ×40.
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Figure 4 Gene silencing of RABEX-5 inhibits breast cancer growth in vivo. (A), MCF-7/KD cells and MCF-7/NC cells were injected
subcutaneously into nude mice. Mice were sacrificed after 4 weeks from transplant. (B-D), Tumor volume and tumor weight were measured after
dissection. (B), Tumor volume were recorded 0, 7, 14, 21 and 28 days after after tumor cell inoculated, and the final tumor weight (D) and
volume (C) were determined. (E), MMP-9 protein levels in transplantation tumor samples were analyzed by western blot. GAPDH was used as an
internal control. (F),The immunohistochemistry analysis of MMP-9 expression in tumors derived from MCF-7/NC group and MCF-7/KD group.
Original magnification, ×40. The asterisk indicates statistical significant difference (P<0.05).
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in vitro results and confirmed that the silencing of
RABEX-5 inhibits breast cancer growth and progression by
modulating MMP-9 transcriptional activity. In summary,
RABEX-5 plays an oncogenic role in breast cancer.Discussion
RABEX-5 is a guanine nucleotide exchange factor (GEF)
for RAB-5 [13], a small GTPase that regulates early en-
dosome fusion and endocytosis [17-21]. RABEX-5 was
identified as an interactor of Rabaptin-5 and was found to
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both Rabaptin-5 and RABEX-5 are essential for RAB-
5-driven endosome fusion. Previous studies have reported
that RABEX-5 can specifically bind to the active form of
RAB-5, thereby regulating the docking and fusion of
endosomal membranes, the motility of endosomes and
intracellular signal transduction [22]. It has been demon-
strated that the expression of RAB-5 proteins was associ-
ated with the development of various malignant tumors of
the breast, ovary, and lung [23-25]. However, previous
studies have not yet investigated the association between
RABEX-5 expression and cancer. In the present study, we
demonstrated that RABEX-5 was overexpressed in breast
cancer tissues and breast cancer cells; in addition, the influ-
ence of RABEX-5 on the biological behavior of breast can-
cer cells in vitro and in vivo was investigated. Our results
argue that RABEX-5 may have an oncogenic effect on
breast cancer.
In this study, we found that RABEX-5 was clearly
overexpressed in all 5 breast cancer cell lines (MCF-7,
MDA-MB-231, T47D, BT549, and SKBR3) and breast can-
cer tissues that were tested. In contRast, RABEX-5 was
expressed at low levels in benign breast tumor tissues and
normal breast tissues. The high expression of RABEX-5 in
breast cancer cells was consistent with the results obtained
from other tumors [14], which indicates that RABEX-5
was involved in tumorigenesis. To explore the importance,
role and function of RABEX-5 and to determine how
RABEX-5 affects the proliferation, growth, invasion and
migration of breast cancer cells, RNAi was used to sup-
press the expression of RABEX-5. In our studies, four pairs
of siRNAs that targeted RABEX-5 and one negative control
siRNA were designed. Compared with other gene knock-
out techniques, this technique is highly efficient, specific,
stable, transmissible and hereditable; therefore, it plays an
important role in gene function research and gene therapy
of tumors [26]. Thus, a lentiviral vector for RNA interfer-
ence (RNAi) of the RABEX-5 gene was constructed to si-
lence the expression of RABEX-5 in MCF-7 cells.
Real-time PCR and western blots confirmed that the
expression of RABEX-5 was suppressed in MCF-7/KD
cells. In addition, the colony formation assay and CCK-8
assay demonstrated that the silencing of RABEX-5 al-
tered the proliferation and growth of the cells. After the
transfection of RABEX-5 siRNA into MCF-7 cells, the
invasion and migration capacities of the cells were sig-
nificantly altered, as shown by transwell cell invasion
and wound healing assays. To further investigate the role
of RABEX-5 in tumorigenesis, we established transplanted
tumor models in mice, and the results were consisted with
our in vitro results. These data suggest a potential role for
RABEX-5 in the onset of carcinogenesis in breast cancer.
We also studied the expression of RABEX-5 in 60 cases of
breast cancer patients and found that RABEX-5 expressionwas related to axillary lymph node metastasis, which fur-
ther demonstrated that RABEX-5 played an important role
in breast cancer metastasis. In this study, we showed that
RABEX-5 potentially acts as a poor prognostic factor for
breast cancer because it is associated with the onset of
breast cancer and increased metastasis. Thus, it might be-
come a promising therapeutic target for breast cancer.
RABEX-5 inhibition resulted in decreased proliferation
and metastasis of breast cancer cells. However, the mech-
anism remains unclear. MMP-9 is one of the most import-
ant members of the MMPs (matrix metalloproteinases). It
is produced predominantly by leukocytes and has been ex-
tensively studied in cancer and other diseases [27]. MMP-9
is required for physiological processes such as ECM re-
modeling during growth and development, inflammation,
wound healing, angiogenesis, and leukocyte mobilization.
It is also involved in pathological processes such as cancer,
inflammation, and neural and vascular degenerative dis-
eases [16,28,29]. Early research showed that MMP-9 had a
distinct role in tumor angiogenesis, mainly through its abil-
ity to regulate the bioavailability of vascular endothelial
growth factor (VEGF) [30]. Furthermore, MMP-9 was
previously shown to play a critical role in maintaining
the tumor microenvironment, leading to enhanced can-
cer cell motility and cancer growth [16]. In this study,
we showed that RABEX-5 silencing triggered a de-
crease in MMP-9 activation. Therefore, we hypothesize
that RABEX-5 promotes the migration and invasion of
breast cancer cells through activation of MMP-9.
In conclusion, we found that RABEX-5 expression in
breast cancer tissues was significantly higher than in nor-
mal breast tissues and benign breast tumor tissues, and it
correlated with the clinical feature of axillary lymph node
metastasis. Moreover, overexpression of RABEX-5 pro-
motes tumor growth, migration and invasion of breast
cancer cells in vitro and in transplanted tumor models.
RABEX-5 plays an important oncogenic role in breast can-
cer. It may also serve as a useful indicator for tumor pro-
gression and metastasis, and its effects might be partially
mediated by modulation of MMP-9 activation.
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